Randomized trials of dopamine agonists in restless legs syndrome: A systematic review, quality assessment, and meta-analysis

Clinical Therapeutics

Volumn 32, Issue 2, 2010, Pages 221-237

  Zintzaras, Elias ^a,b   Kitsios, Georgios D ^a,b   Papathanasiou, Afroditi A ^a   Konitsiotis, Spiros ^c   Miligkos, Michael ^a   Rodopoulou, Paraskevi ^a   Hadjigeorgiou, George M ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

CONSORT; dopamine agonists; efficacy; meta analysis; quality; restless legs syndrome

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SUMANIROLE;

CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SCORING SYSTEM; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; DOPAMINE AGONISTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77649091106     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.028     Document Type: Review

References (67)

1. Trenkwalder C., Paulus W., and Walters A.S. The restless legs syndrome. Lancet Neurol. 4 (2005) 465-475
2. Earley C.J. Clinical practice. Restless legs syndrome. N Engl J Med. 348 (2003) 2103-2109
3. Schapira A.H. Restless legs syndrome: An update on treatment options. Drugs. 64 (2004) 149-158
4. Allen R.P., Picchietti D., Hening W.A., et al., Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health, International Restless Legs Syndrome Study Group. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 4 (2003) 101-119
5. Barrière G., Cazalets J.R., Bioulac B., et al. The restless legs syndrome. Prog Neurobiol. 77 (2005) 139-165
6. Taşdemir M, Erdoǧan H, Börü UT, et al. Epidemiology of restless legs syndrome in Turkish adults on the western Black Sea coast of Turkey: A door-to-door study in a rural area [published online ahead of print April 27, 2009]. Sleep Med.
7. Nomura T., Inoue Y., Kusumi M., et al. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord. 23 (2008) 2363-2369
8. Zucconi M., and Ferini-Strambi L. Epidemiology and clinical findings of restless legs syndrome. Sleep Med. 5 (2004) 293-299
9. Hadjigeorgiou G.M., Stefanidis I., Dardiotis E., et al. Low RLS prevalence and awareness in central Greece: An epi-demiological survey. Eur J Neurol. 14 (2007) 1275-1280
10. Silber M.H., Ehrenberg B.L., Allen R.P., et al., Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome [published correction appears in Mayo Clin Proc. 2004;79:1341]. Mayo Clin Proc. 79 (2004) 916-922
11. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol. 39 (1982) 739
12. Garcia-Borreguero D., Kohnen R., Högl B., et al. Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med. 8 (2007) 455-463
13. Hening W.A. Current guidelines and standards of practice for restless legs syndrome. Am J Med. 120 Suppl 1 (2007) S22-S27
14. Trenkwalder C., Hening W.A., Montagna P., et al. Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov Disord. 23 (2008) 2267-2302
15. Moher D., Jadad A.R., and Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 12 (1996) 195-208
16. Kaptchuk T.J. The double-blind, randomized, placebo-controlled trial: Gold standard or golden calf?. J Clin Epidemiol. 54 (2001) 541-549
17. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 357 (2001) 1191-1194
18. Begg C., Cho M., Eastwood S., et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 276 (1996) 637-639
19. Ziogas D.C., and Zintzaras E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. Ann Epidemiol. 19 (2009) 494-500
20. Partsinevelou A., and Zintzaras E. Quality of reporting of randomized controlled trials in polycystic ovary syndrome. Trials. 10 (2009) 106
21. Partinen M., Hirvonen K., Jama L., et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose-finding study-the PRELUDE study. Sleep Med. 7 (2006) 407-417
22. Winkelman J.W., Sethi K.D., Kushida C.A., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 67 (2006) 1034-1039
23. Trenkwalder C., Stiasny-Kolster K., Kupsch A., et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 21 (2006) 1404-1410
24. Oertel W.H., Stiasny-Kolster K., Bergtholdt B., et al., Pramipexole RLS Study Group. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 22 (2007) 213-219
25. Ferini-Strambi L., Aarskog D., Partinen M., et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. Sleep Med. 9 (2008) 874-881
26. Trenkwalder C., Garcia-Borreguero D., Montagna P., et al., Therapy with Ropiunirole, Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 75 (2004) 92-97
27. Walters A.S., Ondo W.G., Dreykluft T., et al., TREAT RLS 2 (Therapy with Ropinirole: Efficacy And Tolerability in RLS 2) Study Group. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, doubleblind, randomized, parallel-group, placebo-controlled study. Mov Disord. 19 (2004) 1414-1423
28. Bogan R.K., Fry J.M., Schmidt M.H., et al., TREAT RLS US Study Group. Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 81 (2006) 17-27
29. Trenkwalder C., Hundemer H.P., Lledo A., et al., PEARLS Study Group. Efficacy of pergolide in treatment of restless legs syndrome: The PEARLS Study. Neurology. 62 (2004) 1391-1397
30. Stiasny-Kolster K., Benes H., Peglau I., et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 63 (2004) 2272-2279
31. Oertel W.H., Benes H., Garcia-Borreguero D., et al., Rotigotine SP 709 Study Group. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. 9 (2008) 228-239
32. Garcia-Borreguero D., Winkelman J., Adams A., et al., Sumanirole in RLS Study Group. Efficacy and tolerability of sumanirole in restless legs syndrome: A phase II, randomized, double-blind, placebo-controlled, dose-response study. Sleep Med. 8 (2007) 119-127
33. Stiasny-Kolster K., Kohnen R., Schollmayer E., et al., Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double-blind, placebocontrolled pilot study. Mov Disord. 19 (2004) 1432-1438
34. Oertel W.H., Benes H., Bodenschatz R., et al. Efficacy of cabergoline in restless legs syndrome: A placebo-controlled study with polysomnography (CATOR). Neurology. 67 (2006) 1040-1046
35. Trenkwalder C., Benes H., Poewe W., et al., SP790 Study Group. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: A randomised, doubleblind, placebo-controlled trial. Lancet Neurol. 7 (2008) 595-604
36. Montplaisir J., Karrasch J., Haan J., and Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: A randomized controlled trial. Mov Disord. 21 (2006) 1627-1635
37. Kushida C.A., Geyer J., Tolson J.M., and Asgharian A. Patient- and physicianrated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome. Clin Neuropharmacol. 31 (2008) 281-286
38. Jama L., Hirvonen K., Partinen M., et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: Polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med. 10 (2009) 630-636
39. Walters A.S., LeBrocq C., Dhar A., et al., International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 4 (2003) 121-132
40. Walters A.S., and International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord. 10 (1995) 634-642
41. Cooper H., and Hedges L.V. The Handbook of Research Synthesis (1994), Russell Sage Foundation, New York, NY
42. Hedges L.V., and Olkin I. Statistical Methods for Meta-Analysis (1985), Academic Press, Orlando, Fla
43. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials. 7 (1986) 177-188
44. Mulrow C.D., and Oxman A.D. Cochrane Collaboration Handbook (1996), Cochrane Collaboration, Oxford, UK
45. Whitehead A. Meta-Analysis of Controlled Clinical Trials (2002), John Wiley & Sons, Chichester, UK; New York, NY
46. Ioannidis J.P., Trikalinos T.A., and Zintzaras E. Extreme between-study homogeneity in meta-analyses could offer useful insights. J Clin Epidemiol. 59 (2006) 1023-1032
47. Zintzaras E., Chatzoulis D.Z., Karabatsas C.H., and Stefanidis I. The relationship between C677T methylene-tetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: A meta-analysis. J Hum Genet. 50 (2005) 267-275
48. Zintzaras E., Dahabreh I.J., Giannouli S., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of dosage regimens. Clin Ther. 30 (2008) 1939-1955
49. Zintzaras E., and Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 61 (2008) 634-645
50. Lau J., Antman E.M., Jimenez-Silva J., et al. Cumulative meta-analysis of therapeutic trials for myocardial in- farction. N Engl J Med. 327 (1992) 248-254
51. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315 (1997) 629-634
52. Montplaisir J., Nicolas A., Denesle R., and Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: A double-blind randomized trial. Neurology. 52 (1999) 938-943
53. Allen R., Becker P.M., Bogan R., et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 27 (2004) 907-914
54. Earley C.J., Yaffee J.B., and Allen R.P. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology. 51 (1998) 1599-1602
55. Wetter T.C., Stiasny K., Winkelmann J., et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 52 (1999) 944-950
56. Bliwise D.L., Freeman A., Ingram C.D., et al. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med. 6 (2005) 141-147
57. Benes H. Transdermal lisuride: Short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med. 7 (2006) 31-35
58. Benes H., Deissler A., Rodenbeck A., et al. Lisuride treatment of restless legs syndrome: First studies with monotherapy in de novo patients and in combination with levodopa in advanced disease. J Neural Transm. 113 (2006) 87-92
59. Walters A.S., Hening W.A., Kavey N., et al. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol. 24 (1988) 455-458
60. Kohnen R. The promises of meta-analyses in current RLS research: Is 1+1 more than 2?. Sleep Med. 9 (2008) 709-711
61. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 356 (2007) 39-46
62. Hill C.L., LaValley M.P., and Felson D.T. Discrepancy between published report and actual conduct of randomized clinical trials. J Clin Epidemiol. 55 (2002) 783-786
63. Balk E.M., Bonis P.A., Moskowitz H., et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 287 (2002) 2973-2982
64. Quilici S., Abrams K.R., Nicolas A., et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med. 9 (2008) 715-726
65. Baker W.L., White C.M., and Coleman C.I. Effect of nonergot dopamine agonists on symptoms of restless legs syndrome. Ann Fam Med. 6 (2008) 253-262
66. Allen R.P., and Earley C.J. Restless legs syndrome: A review of clinical and pathophysiologic features. J Clin Neurophysiol. 18 (2001) 128-147
67. Fulda S., and Wetter T.C. Where dopamine meets opioids: A meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 131 (2008) 902-917